Brian F. Mandell, MD, PhD

Brian F. Mandell, MD, PhD
Editor in Chief
 

Brian F. Mandell, MD, PhD
Editor in Chief
 

Brian F. Mandell, MD, PhD
Editor in Chief
 

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Editor in Chief

Brian F. Mandell, MD, PhD
Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Vice Chairman of Medicine for Educational Affairs, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Division of Education, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Oh 44195; e-mail [email protected]

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Brian F. Mandell, MD, PhD
Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Vice Chairman of Medicine for Educational Affairs, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Division of Education, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Oh 44195; e-mail [email protected]

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Brian F. Mandell, MD, PhD
Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Vice Chairman of Medicine for Educational Affairs, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Division of Education, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Oh 44195; e-mail [email protected]

Medical Grand Rounds articles are based on edited transcripts from Division of Medicine Grand Rounds presentations at The Cleveland Clinic. They are approved by the author but are not peer-reviewed.

This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.

Brian F. Mandell, MD, PhD
Deputy Editor, Cleveland Clinic Journal of Medicine

Brian F. Mandell, MD, PhD
Deputy Editor, Cleveland Clinic Journal of Medicine

Brian F. Mandell, MD, PhD
Deputy Editor, Cleveland Clinic Journal of Medicine